Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention

• Autores: Robert W. Yeh, Eric A. Secemsky, Dean J. Kereiakes, T. Normand Sharon-Lise
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 311, Nº. 1, 2014, págs. 1735-1749
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Importance Dual antiplatelet therapy after percutaneous coronary intervention (PCI) reduces ischemia but increases bleeding.

    Objective To develop a clinical decision tool to identify patients expected to derive benefit vs harm from continuing thienopyridine beyond 1 year after PCI.